Lecture
This lecture covers the use of monoclonal antibodies in cancer treatment, focusing on targeting specific antigens and immunosuppressive mechanisms. It explains how antibodies like Herceptin and Rituximab work, as well as newer immune checkpoint inhibitors like CTLA-4 and PD-1. The instructor details the mechanisms of action of these antibodies, including activating immune responses, blocking immunosuppression, and inducing cytotoxic effects. The lecture also discusses the role of Tregs and CD8 T cells in tumor-associated immunosuppression, emphasizing the importance of understanding these interactions for developing effective therapies.